Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 5/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SCN4A | P35499 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2898129 | 1.00 | FKBP1A (0.58) | FKBP1AHSD17B10SMN1; SMN2NPC1LMNA | |
| SCHEMBL2737884 | 1.00 | FKBP1A (0.58) | FKBP1AHSD17B10SMN1; SMN2NPC1LMNA | |
| SCHEMBL2738084 | 0.98 | FKBP1A (0.57) | FKBP1AHSD17B10SMN1; SMN2NPC1LMNA | |
| SCHEMBL18455416 | 0.98 | FKBP1A (0.57) | FKBP1AHSD17B10SMN1; SMN2NPC1LMNA | |
| SCHEMBL883030 | 0.95 | HSD17B10 (0.58) | FKBP1AHSD17B10SMN1; SMN2NPC1LMNA | |
| SCHEMBL1486184 | 0.95 | HSD17B10 (0.58) | FKBP1AHSD17B10SMN1; SMN2NPC1LMNA | |
| SCHEMBL190042 | 0.95 | HSD17B10 (0.58) | FKBP1AHSD17B10SMN1; SMN2NPC1LMNA | |
| Hydrochloric Acid SCHEMBL29889454 | 0.94 | HSD17B10 (0.57) | FKBP1AHSD17B10SMN1; SMN2NPC1LMNA | |
| SCHEMBL927348 | 0.90 | HSD17B10 (0.56) | FKBP1AHSD17B10SMN1; SMN2NPC1LMNA | |
| SCHEMBL28153746 | 0.90 | HSD17B10 (0.56) | FKBP1AHSD17B10SMN1; SMN2NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4097093-B1 | PROCESSES FOR THE PREPARATION OF GLASDEGIB AND SALT THEREOF AND SOLID STATE FORMS OF GLASDEGIB MALEATE AND PROCESS FOR PREPARATION THEREOF | TEVA PHARMACEUTICALS INT GMBH (CH) | 2024-01-24 | — | — | EP | disclosed |
| CN-111757884-B | Substituted macrocyclic indole derivatives | 拜耳股份公司 | 2023-12-19 | — | — | CN | disclosed |
| WO-2021154901-A1 | PROCESSES FOR THE PREPARATION OF GLASDEGIB AND SALT THEREOF AND SOLID STATE FORMS OF GLASDEGIB MALEATE AND PROCESS FOR PREPARATION THEREOF | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2021-08-05 | — | — | WO | disclosed |
| US-20160214958-A1 | COMPOUNDS AND USE FOR TREATING CANCER | GLIONOVA AB (SE) | 2016-07-28 | — | — | US | disclosed |
| US-20160214958-A1 | COMPOUNDS AND USE FOR TREATING CANCER | GLIONOVA AB (SE) | 2016-07-28 | — | — | US | disclosed |
| US-20110237511-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK FROSST CANADA (CA) | 2011-09-29 | — | — | US | disclosed |
| US-RE42562-E1 | EP4 receptor agonist, compositions and methods thereof | MERCK FROSST CANADA (CA) | 2011-07-19 | — | — | US | disclosed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| WO-2007130820-A2 | MGLUR5 MODULATORS I | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-7238710-B2 | EP4 receptor agonist, compositions and methods thereof | MERCK FROSST CANADA, LTD. (CA) | 2007-07-03 | — | — | US | disclosed |
| US-5409946-A | Antiepileptic agent | ABBOTT LABORATORIES (US) | 1995-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | FKBP1A 673/4885HSD17B10 2742/4885SMN1; SMN2 1207/4885 |
| US-20070259916-A1 | mGluR5 modulators II | GRM5, GRM2, GRIK5 | FKBP1A 822/4885HSD17B10 2632/4885SMN1; SMN2 1076/4885 |
| US-20160214958-A1 | COMPOUNDS AND USE FOR TREATING CANCER | KRAS, NRAS, HRAS | FKBP1A 3478/4885HSD17B10 4184/4885SMN1; SMN2 4779/4885 |
| US-20110237511-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | PTGER4, PTGER1, PTGER3 | FKBP1A 1866/4885HSD17B10 3624/4885SMN1; SMN2 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.